Simple, sensitive and rapid determination of linifanib (ABT-869), a novel tyrosine kinase inhibitor in rat plasma by UHPLC-MS/MS

Chemistry Central Journal

Muzaffar Iqbal¹  Essam Ezzeldin¹  Tanveer A Wani²  Nasr Y Khalil² 

[1] Bioavailability Laboratory, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh, Saudi Arabia

[2] Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia

关键词: Pharmacokinetics;    Rat plasma;    UHPLC-MS/MS;    ABT-869;    Linifanib;   

Others  :  787798
DOI  :  10.1186/1752-153X-8-13

 received in 2013-11-28, accepted in 2014-02-12,  发布年份 2014

【 摘 要 】

Background

Linifanib (ABT-869) is an orally active receptor tyrosine kinase inhibitor, which simultaneously inhibits vascular endothelial and platelet derived growth factor receptor. The aim of the present study was to develop an UHPLC-MS/MS method for the quantification of linifanib in rat plasma to support the pharmacokinetic and toxicokinetic studies.

Results

Linifanib was separated on Acquity UPLC BEH™ C₁₈ column (50 × 2.1 mm, i.d. 1.7 μm) using acetonitrile-10 mM ammonium acetate (60:40, v/v) as an isocratic mobile phase at a flow rate of 0.3 mL/min with sunitinib as internal standard (IS). Detection was performed on tandem mass spectrometer using electrospray ionization source in positive mode by multiple reaction monitoring. The monitored transitions were set at m/z 376.05 > 250.97 for linifanib and m/z 399.12 >283.02 for IS, respectively. Both linifanib and IS were eluted at 0.68 and 0.44 min, respectively with a total run time of 2.0 min only. The calibration curve was found to be linear over the concentration range of 0.40–500 ng/mL. The intra- and inter-day precision value was ≤10.6% and the accuracy ranged from 90.9-108.9%. In addition, all the validation results were within general assay acceptability criteria according to guidelines of bio-analytical method validation.

Conclusion

A selective and sensitive UHPLC-MS/MS method was developed and validated for the determination of linifanib in rat plasma for the first time. The developed method is simple, sensitive and rapid in terms of chromatographic separation and sample preparation and was successfully applied in a pilot pharmacokinetic study in rats.

【 授权许可】

   
2014 Iqbal et al.; licensee Chemistry Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003, 111(9):1287-1295.
• [2]Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P: Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004, 18(2):338-340.
• [3]Dai Y, Hartandi K, Ji Z, Ahmed AA, Albert DH, Bauch JL, Bouska JJ, Bousquet PF, Cunha GA, Glaser KB, et al.: Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. J Med Chem 2007, 50(7):1584-1597.
• [4]Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Wei RQ, Li J, Guo J, Bousquet PF, Ghoreishi-Haack NS, et al.: Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006, 5(4):995-1006.
• [5]Guo J, Marcotte PA, McCall JO, Dai Y, Pease LJ, Michaelides MR, Davidsen SK, Glaser KB: Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther 2006, 5(4):1007-1013.
• [6]Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, et al.: Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol 2011, 6(8):1418-1425.
• [7]Toh HC, Chen PJ, Carr BI, Knox JJ, Gill S, Ansell P, McKeegan EM, Dowell B, Pedersen M, Qin Q, et al.: Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer 2013, 119(2):380-387.
• [8]Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, Posadas EM, Cho D, Choueiri TK, Coates A, et al.: Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer 2011, 47(18):2706-2714.
• [9]Chiu YL, Carlson DM, Pradhan RS, Ricker JL: Exposure-response (safety) analysis to identify linifanib dose for a phase III study in patients with hepatocellular carcinoma. Clin Ther 2013, 35(11):1770-1777.
• [10]Asahina H, Tamura Y, Nokihara H, Yamamoto N, Seki Y, Shibata T, Goto Y, Tanioka M, Yamada Y, Coates A, et al.: An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. Cancer Chemother Pharmacol 2012, 69(6):1477-1486.
• [11]Wong CI, Koh TS, Soo R, Hartono S, Thng CH, McKeegan E, Yong WP, Chen CS, Lee SC, Wong J, et al.: Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 2009, 27(28):4718-4726.
• [12]Rodila RC, Kim JC, Ji QC, El-Shourbagy TA: A high-throughput, fully automated liquid/liquid extraction liquid chromatography/mass spectrometry method for the quantitation of a new investigational drug ABT-869 and its metabolite A-849529 in human plasma samples. Rapid Commun Mass Spectrom 2006, 20(20):3067-3075.
• [13]Wu H, Zhang J, Norem K, El-Shourbagy TA: Simultaneous determination of a hydrophobic drug candidate and its metabolite in human plasma with salting-out assisted liquid/liquid extraction using a mass spectrometry friendly salt. J Pharm Biomed Anal 2008, 48(4):1243-1248.
• [14]Kumar A, Saini G, Nair A, Sharma R: UPLC: a preeminent technique in pharmaceutical analysis. Acta Pol Pharm 2012, 69(3):371-380.
• [15]Li F, Maguigad J, Pelzer M, Jiang X, Ji QC: A novel 'peak parking' strategy for ultra-performance liquid chromatography/tandem mass spectrometric detection for enhanced performance of bioanalytical assays. Rapid Commun Mass Spectrom 2008, 22(4):486-494.
• [16]Novakova L, Matysova L, Solich P: Advantages of application of UPLC in pharmaceutical analysis. Talanta 2006, 68(3):908-918.
• [17]US Food and Drug Administration, Center for Drug Evaluation and Research (CDER): Guidance for industry on bioanalytical method validation. Rockville, MD: Department of Health and Human Services; 2001. [http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf webcite]
• [18]European Medicines Agency: Guideline on bioanalytical method validation, 2011. [http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf webcite]
• [19]Phillips GB, Dodge JT: Composition of phospholipids and of phospholipid fatty acids of human plasma. J Lipid Res 1967, 8(6):676-681.